ADORA2A and cancer: A GBM-directed anti-A2AR agent, istradefylline (IST), showed an inferior anti-proliferative effect on cancer cells compared to riluzole, which mainly inhibits a downstream player, Casein kinase I delta (CK1δ) (101).